Immunobiology of Human Cytomegalovirus: from Bench to Bedside

@article{Crough2009ImmunobiologyOH,
  title={Immunobiology of Human Cytomegalovirus: from Bench to Bedside},
  author={Tania Crough and Rajiv Khanna},
  journal={Clinical Microbiology Reviews},
  year={2009},
  volume={22},
  pages={76 - 98}
}
SUMMARY Following primary infection, human cytomegalovirus (HCMV) establishes lifelong latency and periodically reactivates without causing symptoms in healthy individuals. In the absence of an adequate host-derived immune response, this fine balance of permitting viral reactivation without causing pathogenesis is disrupted, and HCMV can subsequently cause invasive disease and an array of damaging indirect immunological effects. Over the last decade, our knowledge of the immune response to HCMV… Expand

Topics from this paper

Epigenetic regulation of human cytomegalovirus latency: an update.
TLDR
The epigenetic regulation of HCMV latency is described, which involves chromatin remodeling by an array of enzymes and microRNAs and the patho-physiological relevance of latent H CMV infection is discussed. Expand
Human Cytomegalovirus and Autoimmune Disease
TLDR
A clear association of H CMV seroprevalence and disease could not be established, leaving the question open whether HCMV could play a coresponsible role for onset of disease. Expand
Infections and autoimmunity: role of human cytomegalovirus in autoimmune endothelial cell damage
TLDR
It is proposed that immune responses to particular HCMV proteins may result in autoaggression through a mechanism of molecular mimicry of normally expressed endothelial cell surface molecules. Expand
CARs—A New Perspective to HCMV Treatment
TLDR
Use of chimeric antigen receptors (CARs), a treatment strategy adapted from cancer immunotherapy, is investigated for possible application to combat HCMV and other infections in immunocompromised patients and the administration of CAR+ T-cells directed against H CMV antigens can bypass viral immune evasion and may complement existing treatment methods. Expand
Controlling Cytomegalovirus: Helping the Immune System Take the Lead
TLDR
A review of many of these studies and insights into how CMV-specific T cells are currently being used therapeutically are provided. Expand
Investigation of mammalian and viral Interleukin-10 family members during cytomegalovirus infection
TLDR
Novel insights into cytokine biology in the context of viral infections in vivo revealed by these studies highlighted important considerations for future research into herpesvirus infections, and has major implications for the treatment of this important infectious disease. Expand
Peptide inhibition of human cytomegalovirus infection
TLDR
Peptides designed to target putative fusogenic domains of gB provide a basis for the development of novel therapeutics that prevent HCMV infection. Expand
Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector.
TLDR
Key features of the basic biology of CMV-specific T cells are discussed as well as unanswered questions and ongoing work in the development of T-cell-based immunotherapies to target CMV are highlighted. Expand
Quantification of cytomegalovirus viral load
TLDR
The indications of CMV quantification include CMV infection during pregnancy and in newborns, and viral surveillance of grafted and non-grafted immunocompromised patients, patients with bowel inflammatory diseases and those hospitalised in intensive care unit. Expand
Towards understanding of Human Cytomegalovirus in Glioblastoma
TLDR
The results suggest that commercial serology tests are not reliable to detect an ongoing or previous HCMV infection in GBM patients, and imply that HCMVs may enhance the malignancy grade of the tumor, and possibly contribute to therapy resistance. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 317 REFERENCES
Vaccine strategies against human cytomegalovirus infection
TLDR
It is proposed that research should focus on the development of a vaccine to prevent or control HCMV-related disease rather than to prevent infection, and that discerning strategies should be used for targeting H CMV disease in different clinical settings. Expand
Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.
TLDR
Immune-based therapies to complement pharmacological strategies for the successful treatment of virus-associated complications should be prospectively investigated. Expand
Progress in cytomegalovirus vaccine development.
  • M. Schleiss
  • Medicine
  • Herpes : the journal of the IHMF
  • 2005
TLDR
An update on CMV vaccines that are currently in preclinical and clinical development is provided, and important, as yet unanswered, questions about the nature of protective immune responses that will be required of potential CMV immunization strategies are outlined. Expand
Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion.
TLDR
The ability of such viral functions to successfully 'face off' against the host immune system ensures the success of this pathogen in the human population and could provide key insights into disease mechanisms. Expand
Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B
TLDR
Glycoprotein B may be an important target for future subunit vaccines as it has been found to elicit both neutralising antibody and CTL responses. Expand
Latency and reactivation of human cytomegalovirus.
TLDR
The accumulating evidence suggesting that reactivation of HCMV from latency appears to be linked intrinsically to the differentiation status of the myeloid cell is addressed, and how the cellular mechanisms that normally control host gene expression play a critical role in the differential regulation of viral gene expression during latency and reactivation are addressed. Expand
Clinical and Immunologic Aspects of Cytomegalovirus Infection in Solid Organ Transplant Recipients
TLDR
Challenges in managing CMV infection in transplant recipients are summarized and current insights in the cellular immune response against CMV are highlighted. Expand
Congenital cytomegalovirus infection: outcome and diagnosis.
TLDR
Newer molecular diagnostic methods to diagnose congenitalCMV infection, including the nucleic acid amplification of viral DNA from the peripheral blood of infants, are being investigated, and the preliminary results show promise, but more work must be done to standardize and validate these methods before they can be used routinely in establishing the diagnosis of congenital CMV infection. Expand
Functional Impairment of Cytomegalovirus Specific CD8 T Cells Predicts High‐Level Replication After Renal Transplantation
  • F. Mattes, A. Vargas, +9 authors V. Emery
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2008
TLDR
It is shown that functional impairment of HCMV specific CD8 T cells in the production of interferon gamma was associated with a 14‐fold increased risk of progression to high level replication and this results help to explain why a subset of seropositive individuals develop H CMV replication and are at risk of end‐organ disease. Expand
Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro.
TLDR
This is the first functional demonstration of a virus-coded sequence required for HCMV latency, and UL138 RNA was expressed in CD34(+) cells and monocytes from HCMv-seropositive, healthy individuals, suggesting it might be a target for antivirals against latent virus. Expand
...
1
2
3
4
5
...